bluuebunny/crossref_metadata_2025_split huggingface dataset:
Inferring the jet parameters of active galactic nuclei using Bayesian analysis of VLBI data with a non-uniform jet model
Authors: Pashchenko Ilya N , Plavin Alexander V 
Published: June 2019

ABSTRACTThe physical parameters of the jets of active galactic nuclei observed with Very Long Baseline Interferometry (VLBI) are usually inferred from core-shift measurements or from the flux and size measured at the peak frequency of the synchrotron spectrum. Both methods are preceded by modelling the observed VLBI jet structure with simple Gaussian templates. Here we infer the jet parameters using an inhomogeneous jet model directly, bypassing the modelling of the source structure with a Gaussian template or image deconvolution. We apply Bayesian analysis to multifrequency VLBA observations of radio galaxy NGC 315 and find that its parsec-scale jet is well described by an inhomogeneous conical model. Our results favour an electron–positron jet. We also detect a component as a part of a counter jet. Its position implies the presence of an external absorber with a steep density gradient close (r = 0.1 pc) to the central engine.
Statistical analysis of roAp, He-weak, and He-rich stars
Authors: Ghazaryan S , Alecian G , Hakobyan A A 
Published: June 2019

Abstract
To enlarge our data base of chemically peculiar stars, we compiled published data concerning the He-weak and He-rich stars observed by high-resolution spectroscopy techniques during last decades. Twenty He-weak and 28 He-rich stars have been added to the data base. We have also distinguished roAp stars from stars previously identified as Ap stars. To deepen our knowledge on statistical overview of the abundance anomalies versus the physical parameters of stars, we compared our data with previous compilations. We applied statistical tests on our data and found interesting correlations for effective temperature and surface gravity for all type of stars and a few correlations for projected rotation velocity only for He-rich stars. Because of the lack of the data, we could not check whether being a member of binary system is affecting on chemical peculiarities of those stars.
The ASAS-SN catalogue of variable stars – IV. Periodic variables in the APOGEE survey
Authors: Pawlak Michał , Pejcha O , Jakubčík P , Jayasinghe T , Kochanek C S , Stanek K Z , Shappee B J , Holoien T W-S , Thompson Todd A , Prieto J L , Dong S , Shields J V , Pojmanski G , Britt C A , Will D 
Published: June 2019

ABSTRACT
We explore the synergy between photometric and spectroscopic surveys by searching for periodic variable stars among the targets observed by the Apache Point Observatory Galactic Evolution Experiment (APOGEE) using photometry from the All-Sky Automated Survey for Supernovae (ASAS-SN). We identified 1924 periodic variables among more than $258\, 000$ APOGEE targets; 465 are new discoveries. We homogeneously classified 430 eclipsing and ellipsoidal binaries, 139 classical pulsators (Cepheids, RR Lyrae, and δ Scuti), 719 long-period variables (pulsating red giants), and 636 rotational variables. The search was performed using both visual inspection and machine learning techniques. The light curves were also modelled with the damped random walk stochastic process. We find that the median [Fe/H] of variable objects is lower by 0.3 dex than that of the overall APOGEE sample. Eclipsing binaries and ellipsoidal variables are shifted to a lower median [Fe/H] by 0.2 dex. Eclipsing binaries and rotational variables exhibit significantly broader spectral lines than the rest of the sample. We make ASAS-SN light curves for all the APOGEE stars publicly available and provide parameters for the variable objects.
Redshift-space distortions of the H i 21-cm intensity mapping signal due to the internal motions within galaxies
Authors: Sarkar Debanjan , Bharadwaj Somnath 
Published: June 2019

ABSTRACTThe H i 21-cm intensity mapping signal experiences redshift-space distortions due to the motion of the galaxies which contain the H i as well as the motions of the H i gas within the galaxies. A detailed modelling is essential if this signal is to be used for precision cosmology. Considering dark-matter-only simulations where the H i is assumed to reside in galaxies which are associated with haloes, in this work we introduce a technique to incorporate the H i motions within the galaxies. This is achieved through a line profile which accounts for both the rotational and random (thermal and turbulent) motions of the H i within galaxies. The functional form of the double-horned line profiles used here is motivated by observations of z = 0 spiral galaxies. Analyzing the simulated 21-cm power spectrum over the redshift range 1 ≤ z ≤ 6 we find that the H i motions within galaxies make a significant contribution that is manifested as an enhancement in the Finger of God (FoG) effect which can be modelled reasonably well through a Lorentzian damping profile with a single free parameter σp. The value of σp is significantly enhanced if motions within the galaxies are included. This is particularly important at z > 3 where σp is dominated by the internal motions and a measurement of the FoG effect here could provide a handle on the line profiles of high-redshift galaxies.
Incentives and Competition in the Airline Industry
Authors: Aggarwal Rajesh K , Schenone Carola 
Published: June 2019

AbstractWe examine how performance changes at airlines in response to a change in executive incentives. Airlines with executive bonuses contingent on on-time arrival do improve on-time performance. We find evidence of strategic gaming of the incentive as some carriers increase scheduled flight times, making it easier for flights to arrive on time. This effect is more pronounced for competitive routes. Carriers also do not decrease the frequency of flights or the number of passengers to make it easier to be on time, but they do slightly decrease fares. Competitors on the same routes also improve their on-time performance, even when their executive bonuses are not contingent on on-time performance, consistent with competition in strategic complements. (JEL G30, G34, G32)Received February 5, 2018; editorial decision April 3, 2019 by Editor Andrew Ellul.
S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD
Authors: Baron F. , Labopin M. , Ruggeri A. , Sierra J. , Robinson S. , Labussière‐Wallet H. , Potter M. , Ribera Santasusana J. M. , Deconinck E. , Rambaldi A. , Rohrlich P.‐S. , de Revel T. , Gluckman E. , Nagler A. , Mohty M. 
Published: June 2019

Background:Cord blood transplantation (CBT) has been associated with good transplantation outcomes in acute leukemia patients with mesurable residual disease (MRD) at transplantation (Milano et al., N Engl J Med 375 :944–953, 2016).Aims:In the current retrospective analysis we assessed the impact of MRD positivity on CBT outcomes.Methods:Inclusion criteria were adult patients with acute myeloid (AML) or lymphoblastic (ALL) leukemia, undergoing CBT as first allogeneic hematopoietic cell transplantation from 2002–2017, first or second complete remission (CR) at transplantation, and available MRD status at the time of transplantation.Results:Data from 506 patients were included in the survey. Among them, 317 patients had AML and 189 ALL (including 102 patients with Phi‐pos ALL). Patients received either a single unit (n = 227) or a double CBT (n = 279). MRD positivity was reported in 169 patients (33%) while the remaining 337 patients were MRD negative at CBT. MRD was more frequently detected in ALL than in AML patients (P = 0.02), in patients given single CBT than in those receiving double CBT (P = 0.02), and in those given in vivo T‐cell depletion of the graft (P = 0.006). At 2 years, relapse incidence was 18% in patients with MRD negativity versus 33% in those with MRD positivity at transplantation (P < 0.001). Two‐year leukemia‐free survival (LFS) and overall survival (OS) were 57% and 60%, respectively, in MRD negative patients, versus 38% (P < 0.001) and 48% (P = 0.004), respectively, in those with MRD positivity. There was no statistical interaction between the impact of MRD positivity and disease type (AML versus ALL) nor disease status at transplantation (first versus second CR). In multivariate analyses, MRD positivity was associated with a higher risk of relapse (HR = 1.8, P = 0.003), comparable non‐relapse mortality (P = 0.44), worse LFS (HR = 1.4, P = 0.008) and a trend for worse OS (HR = 1.3, P = 0.065). Other factors associated with relapse incidence included reduced‐intensity conditionng (RIC) (HR = 1.8, P = 0.01) and in vivo T cell depletion (HR = 2.2, P < 0.001). Other factors associated with worse LFS included CR2 at transplantation (HR = 1.3, P = 0.04) as well as in vivo T cell depletion (HR = 1.9, P < 0.001)Summary/Conclusion:In acute leukemia patients undergoing CBT achieving MRD negativity at time of transplantation is associated with a lower risk of relapse translated into better LFS. Novel strategies are in need for those leukemic patients with positive MRD pre‐CBT aiming at achieving MRD negativity and thus improving transplantation results.
PF178 DEFINITION OF REPRESENTATIVE BONE MARROW SAMPLE BASED ON PARALLEL EVALUATION OF PERIPHERAL BLOOD DURING THE THERAPY OF ACUTE LYMPHOBLASTIC LEUKEMIA
Authors: Vakrmanova B. , Novakova M. , Stary J. , Hrusak O. , Mejstrikova E. 
Published: June 2019

Background:Acute lymphoblastic leukemia (ALL) treatment leads to elimination of the blasts and subsequent regeneration of non‐malignant populations. Amount of minimal residual disease (MRD) is the strongest prognostic marker and its value differs between bone marrow (BM) and peripheral blood (PB). Therefore for patients stratification is necessary to evaluate non‐hemodiluted BM sample. Our AIEOP BFM 2009 protocol considers a BM sample non‐hemodiluted if >2% of its cells are erythroid precursors (EP). EPs are defined as CD19neg(orCD7neg)CD45neg cellsAims:1. To evaluate utility of the currently used marker of BM representativeness.2. To define new, more exact approach for definition of representative BM.Methods:Patients (n = 528) diagnosed with ALL between 2007 and 2015 were included into the study. We analyzed proportion of EPs defined as CD19neg(orCD7neg)CD45neg in BM and in parallel also in PB at day 15 together with viability dye DAPI. We tested whether a new definition of EPs including an added CD71 marker (transferrin receptor expressed since early phases of erythropoiesis) improves its specificity.Then we evaluated other non‐malignant populations (n = 342) in BM and PB for the new definition of representative BM (lymphocytes, granulocytes, monocytes, erythroid precursors, mature B cells, T cells and NK cells in both B cell precursor and T ALL; CD4+, CD8+ and CD4negCD8neg T lymphocytes in T ALL only).Results:1. We identified high proportion of apoptotic cells in EPs defined as CD19neg(orCD7neg)CD45neg (6.5–96%, median 55%) The population defined as CD19neg(orCD7neg)CD45negCD71pos was more viable (apoptotic cells 0–66%, median 9%) p < 0.0001. Then we evaluated population CD19neg(orCD7neg)CD45neg in PB. We found that as many as 29% of PB samples have >2% of EP (the value that is currently used as a marker of BM without hemodilution).2. We defined a new assessment of BM representativeness based on comparison of non‐malignant populations between BM and PB. With increasing difference between the proportion of any population between BM and PB, the possibility of hemodilution lowers. According to this approach we can calculate maximal possible hemodilution and its influence on stratification of the patient. We evaluated 342 patients with available paired BM‐PB samples and identified 6 patients with highly hemodiluted BM samples who might have been misstratified.Summary/Conclusion:We defined a new, more accurate approach for assessment of BM representativeness by comparison of non‐malignant populations between PB and BM. By this approach we can exclude hemodilution in majority of the samples.The currently used marker of representativeness – proportion of EPs, defined as CD19neg(orCD7neg)CD45neg – is not sufficient for assessment of BM representativeness. If proportion of EPs is required, CD71 should be added for the definition.Supported by grants NV18–03–00343, NV18–07–00430 and LO1604.
PF192 CLINICAL PROFILE OF POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN HAEMATOLOGY PATIENTS AT A TERTIARY CARE CENTRE
Authors: Gupta G. , Seth T. , Mahapatra M. , Aggarwal M. , Dhawan R. 
Published: June 2019

Background:Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain edema with acute neurological symptoms in patients of renal failure, hypertension and on cytotoxic drugs. Established diagnostic criteria have been lacking and diagnosis can be made on exclusion based on clinical criteria, serum markers, CSFand imaging. The treatment is symptomatic depending on underlying condition. The overall prognosis is favourable but some patients may have long‐term sequale.Aims:To study the clinico‐radiologic profile and outcomes of PRES in hematological disorders.Methods:We retrospectively reviewed clinical and neuroimaging findings of patients diagnosed with PRES from January 2016 ‐ October 2018. PRES was diagnosed based on clinical signs and MRI findings.Results:There were total of 16 patients diagnosed with PRES. There were 7 females and 9 males with age ranging from 2–25 years. Maximum (12/16) patients were ALL on induction chemotherapy (BFM protocol), rest were AML on consolidation high dose cytarabine (HiDAC), thalassemia post HSCT and aplastic anaemia. None of the patients had prior history of seizures, hypertension or evidence of CNS disease. Most patients had hypertension and generalised tonic clonic seizures (GTCS) as presenting complaints. CSF examination done in all was inconclusive. The most common MRI finding (12/16) was bilateral symmetrical subcortical white matter hyperintensity on T2 and FLAIR images in occipital and parietal lobes. Others had frontal lobe, temporal lobe, thalamus and cerebellar involvement. For management cytotoxic drugs werestopped, antihypertensive (amlodipine, labetalol) and anti‐epileptics were started. Most patients experienced normalisation of blood pressure in an average of 8.6 days (range 4–15 days). Two patients expired during the course due to fungal pneumonia and intra‐cerebral haemorrhage respectively. Patients were continued on antiepileptics for 6–12 months after last seizure episode. Antihypertensives were used for period of one month and then tapered off successfully. Most patients (14/16) were discharged and are under our follow up with no active PRES related complications except one patient who has persistence of neurological deficit in the form of right sided hemiparesis.Summary/Conclusion:Amongst patients with hematological malignancy, PRES is especially seen in ALL where steroids are the backbone of induction chemotherapy. Close blood pressure monitoring in settings of induction chemotherapy and immunosuppressive drugs like calcineurin inhibitors should always be prescribed. Early recognition of PRES may facilitate appropriate treatment in a timely manner, conferring a better prognosis. Future studies should be done to address questions like duration of interruption of drug implicated in PRES, if the implicating drug has to be eliminated permanently, optimal duration of anti‐hypertensives and anti‐epileptics.image
PF195 THE IMPACT OF COMORBIDITY ON SURVIVAL OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Authors: Demichelis R. , Chouciño P. , García A. , Ramos R. , Sánchez J.M. , Bourlon C. 
Published: June 2019

Background:Acute lymphoblastic leukemia (ALL) in adults is associated with poor outcomes with long‐term overall survival (OS) of 40%. ALL is more frequent in children, where comorbidity is infrequent. Currently, Hispanic population is characterized by an increasing adult comorbid population. The above, in addition to the high prevalence of ALL in adults, raises the need of knowing the prevalence and impact of comorbidity in adult ALL.Aims:Analyze the impact of comorbidity on OS of adult patients with ALL.Methods:Retrospective study that included >18 year‐old patients with diagnosis of ALL treated and followed between January 2009 and September 2016 at our institution. To evaluate comorbidity, the hematopoietic cell transplant comorbidity index (HCT‐CI) and the Charlson comorbidity index (CCI) were used.Results:We included 176 patients. The adolescent and young adult (AYA) groups represented the 64.8% of the cohort, the additional 35.2% was represented by adults ≥40 year‐old.The most frequent comorbidities were overweight and obesity in 54.4% (AYA 45.6% vs. adults 71.0%; p = 0.001) and type 2 diabetes mellitus in 10.4% (AYA 1.8% vs. adults 25.8%; p < 0.001). Regarding comorbidity scores, 29.1% had HCT‐CI ≥3 (AYA 23.7% vs. adults 39.3%; p = 0.037) and 47.4% a CCI≥1 (AYA 32.7% vs. adults 74.2%; p < 0.001).The induction related mortality rate was 13.6% (AYA 10.5% vs. adults 19.4%, p = 0.113). Independent risk factors at diagnosis related to induction mortality were: total bilirubin >1 g/dL (OR 3.96, 95% CI 1.19–7.37; p = 0.02) and albumin <3.5 g/dL (OR 3.06, 95% CI 1.20–7.82; p = 0.02).The OS was significantly longer in the AYA group when compared to the group of adults >40 years‐old with median OS of 13.8 and 8.0 months respectively (p < 0.001). Patients with lower HCT‐CI scores (HCT‐CI<3 vs. HCT‐CI≥3) and lower CCI (CCI<1 vs. CCI≥) were significantly associated with a better OS survival (HCT‐CI OS 13.1 vs. 7.6 months; p = 0.005 and CCI OS 13.2 vs. 10.1 months, p = 0.003). Interestingly, this impact of comorbidity scores over OS, remained significant in the group of adult patients (HCT‐CI OS 10.8 vs. 4.3 months, p = 0.003 and CCI OS 11.2 vs. 6.7 months; p = 0.044) but not in the AYA group (HCT‐CI OS 14.4 vs. 12.0 months; p = 0.307 and CCI OS 13.7 vs. 14.4 months, p = 0.471). On multivariate analysis, HCT‐CI ≥3 (HR 1.59, 95% CI 1.06–2.39, p = 0.026), age >40 years (HR 1.69, 95% CI 1.14–2.51, p = 0.009), and achievement of complete remission with the first induction chemotherapy regimen (HR: 0.317, 95% CI 0.217–0.462, p>0.001) were independent prognostic factor for OS.Summary/Conclusion:There are no previous reports analyzing the impact of comorbidities in adults with ALL. This study shows that both HCT‐CI≥3 and CCI ≥1 are associated with poor outcomes in adults ≥ 40 years. The high prevalence of overweight/obesity and diabetes in our patients urges the need for an objective assessment of comorbidities at diagnosis.image
PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3‐MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO‐MUTATIONS OR A HIGH FLT3‐ITD ALLELIC RATIO
Authors: Levis M. , Perl A. , Martinelli G. , Cortes J. , Neubauer A. , Berman E. , Montesinos P. , Baer M. , Larson R. , Chou W.‐C. , Yokoyama H. , Recher C. , Yoon S.‐S. , Hill J. , Rosales M. , Liu C. , Bahceci E. 
Published: June 2019

Background:Treatment with the FLT3 inhibitor, gilteritinib, resulted in superior response rates and overall survival compared with salvage chemotherapy in patients with FLT3‐mutated (FLT3
mut+) relapsed/refractory AML in the phase 3 ADMIRAL study.Aims:We analyzed the impact of baseline co‐mutations and baseline FLT3‐internal tandem duplication (ITD) allelic ratio on achievement of complete remission/complete remission with partial hematologic recovery (CR/CRh) and overall survival.Methods:A total of 37 recurrently mutated genes in AML (Archer Core Myeloid Panel) were analyzed by next‐generation sequencing; the cutoff for co‐mutation positivity (co‐mut+) was ≥0.027. Baseline FLT3‐ITD allelic ratio (FLT3‐ITD to FLT3 wild‐type DNA) was measured by the LeukoStrat® CDx FLT3 Mutation Assay. The median FLT3‐ITD allelic ratio value of 0.77 was used to define high (≥0.77) vs low (<0.77) FLT3‐ITD allelic ratio.Results:An analysis of 361 FLT3
mut+ patients identified four major co‐mutation cohorts, each with ≥10% of the patients: NPM1 (n = 173; 47.9%), DNMT3A (n = 115; 31.9%), DNMT3A/NPM1 (n = 86; 23.8%), and WT1 (n = 65; 18.0%). In addition, seven patients (1.9%) had all three co‐mutations (ie, NPM1, DNMT3A, and WT1). The gilteritinib arm had superior CR/CRh rates and overall survival across all four major co‐mutation cohorts, with the greatest survival benefit in patients with DNMT3A/NPM1 co‐mut+ (Table). In FLT3‐ITD allelic ratio analyses (n = 335), gilteritinib conferred longer overall survival than salvage chemotherapy in patients with a high or low FLT3‐ITD allelic ratio (gilteritinib: high FLT3‐ITD allelic ratio, 7.1 months vs low FLT3‐ITD allelic ratio, 10.6 months; salvage chemotherapy: high FLT3‐ITD allelic ratio, 4.3 months vs low FLT3‐ITD allelic ratio, 6.9 months). In both arms, overall survival was longer in the low FLT3‐ITD allelic ratio cohort than in the high FLT3‐ITD allelic ratio cohort, but the difference in the gilteritinib arm was not statistically significant (gilteritinib: hazard ratio = 1.341, P = 0.0712; salvage chemotherapy: hazard ratio = 2.01, P = 0.0021).Summary/Conclusion:The ADMIRAL trial shows that the clinical benefit of gilteritinib in FLT3
mut+ relapsed/refractory AML is maintained regardless of NPM1, DNMT3A, DNMT3A/NPM1, or WT1 co‐mut+ or high FLT3‐ITD allelic ratio.image
PF254 RESULTS FROM THE FIRST‐IN‐HUMAN STUDY OF MIVEBRESIB (ABBV‐075), A PAN‐INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Authors: Borthakur G. , Odenike O. , Wolff J.E. , Aldoss I. , Rizzieri D. , Prebet T. , Hu B. , Dinh M.H. , Chen X. , Modi D.A. , Freise K.J. , Jonas B.A. 
Published: June 2019

Background:Bromodomain and extra‐terminal (BET) proteins bind to acetyllysines and upregulate oncogenic target genes. Mivebresib (ABBV‐075) is a pan‐BET inhibitor with antitumor activity in vitro and xenograft models of AML. This 2‐part phase 1 study evaluates the safety and pharmacokinetics of mivebresib at monotherapy or combination dosing schedules in patients with solid tumors (part 1) and acute myeloid leukemia (AML; part 2) (NCT02391480).Aims:Here, we report preliminary data from part 2 in patients with relapsed/refractory (RR) AML.Methods:Mivebresib monotherapy (MIV‐mono), or combined with venetoclax (MIV‐VEN), were administered daily to adult patients with AML. The dose‐limiting toxicity (DLT) period was 28 d.Results:As of Dec 2018, 41 patients (median age: 69 y [range, 29–84]; 19 patients had >2 prior therapies) were enrolled: 19 in MIV‐mono (5 of whom switched to MIV‐combo) and 22 who began treatment in MIV‐VEN cohorts. 23 patients had high cytogenetic risk. Median time on treatment was 28 d (range, 8–562). There were no DLTs. All patients experienced a treatment‐emergent adverse event (AE), most commonly (≥40% patient incidence), fatigue (56%), dysgeusia (46%), decreased appetite (44%), diarrhoea (42%), nausea (42%), vomiting (42%). 40 patients had grade ≥3 AEs (febrile neutropenia (37%), anemia (34%) and thrombocytopenia (32%). 33 patients had serious AEs, most commonly febrile neutropenia (19%). 25 deaths were reported; 15 patients died of causes unrelated to mivebresib and 10 patients due to AML progression. The median best % bone marrow blast change for 26 evaluable patients was −20% (range, −98% to +300%). Gene expression analysis in pre‐ and post‐treatment peripheral blood samples showed that HEXIM1, DCXR and CD93 genes were reliable PD biomarkers of ABBV‐075 which were consistently modulated in a dose‐dependent manner. At the cutoff date, median overall survival for all patients was 2.6 m.Summary/Conclusion:Mivebresib was well tolerated and showed antileukemic effects in patients with RR AML.